

Table 2. Multivariate analysis of potential predictors of a $\geq 50\%$, $\geq 75\%$, or 100% (seizure freedom) reduction in seizure frequency per 28 days relative to baseline (Full Analysis Set)

Variable	50% response			75% response			Seizure freedom		
	OR	95% CI	P-value	OR	95% CI	P-value	OR	95% CI	P-value
Sex (M vs F)	0.60	0.11, 3.38	0.5601	1.09	0.30, 3.95	0.9002	0.36	0.10, 1.27	0.1128
Age (old)	0.96	0.90, 1.03	0.2773	0.98	0.93, 1.03	0.5007	1.01	0.96, 1.05	0.8505
BMI (kg/m ²)	0.99	0.79, 1.25	0.9567	1.03	0.87, 1.23	0.7349	1.09	0.92, 1.30	0.3222
Epilepsy prevalence period (year)	1.11	0.95, 1.28	0.1796	1.03	0.96, 1.11	0.4042	1.05	0.98, 1.13	0.1947
Baseline frequency (number/28 days) of:									
POS with/without SGS	1.27	0.21, 7.64	0.7908	2.61	0.38, 17.76	0.3258	0.45	0.17, 1.21	0.1128
Simple POS without motor signs	0.55	0.07, 4.56	0.5788	0.45	0.05, 3.80	0.4597	1.29	0.39, 4.31	0.6815
Simple POS with motor signs	0.79	0.13, 4.79	0.8006	0.42	0.06, 2.88	0.3783	1.74	0.59, 5.14	0.3192
Complex POS	0.67	0.11, 3.97	0.6604	0.35	0.05, 2.37	0.2845	0.90	0.36, 2.28	0.8294
Past history of disease (Y vs N)	0.90	0.14, 5.64	0.9129	0.52	0.14, 1.94	0.3290	1.08	0.28, 4.10	0.9095
Comorbidity (Y vs N)	1.10	0.16, 7.44	0.9262	2.03	0.48, 8.52	0.3327	4.21	0.95, 18.69	0.0587
Previous medication (Y vs N)	3.47	0.18, 65.63	0.4065	0.38	0.05, 2.88	0.3493	0.23	0.03, 1.51	0.1243
Concomitant medication^a (Y vs N)	4.27	0.33, 55.98	0.2690	4.64	0.65, 33.24	0.1266	6.77	1.07, 42.78	0.0421
Total administration period (days)	1.04	1.01, 1.07	0.0121	1.02	1.00, 1.05	0.0677	1.03	1.00, 1.07	0.0538
Total dosage (mg)	1.00	0.99, 1.00	0.0084	1.00	1.00, 1.00	0.0373	1.00	1.00, 1.00	0.1442

Shaded rows show variables that were significantly associated with a $\geq 50\%$, $\geq 75\%$, and/or 100% response

^aIncludes non-antiepileptic medications

BMI, body mass index; CI, confidence interval; F, female; M, male; N, no; OR, odds ratio; POS, partial-onset seizures; SGS, secondarily generalized seizures; Y, yes